Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma - Results from a comprehensive multi-centre database (CORONA/SATURN-Project)

BJU International

Volumn 112, Issue 7, 2013, Pages 909-916

  Brookman May, Sabine D ^a   May, Matthias ^a   Shariat, Shahrokh F ^b   Novara, Giacomo ^c   Zigeuner, Richard ^d   Cindolo, Luca ^e   De Cobelli, Ottavio ^f   De Nunzio, Cosimo ^g   Pahernik, Sascha ^h   Wirth, Manfred P ⁱ   Longo, Nicola ^j   Simonato, Alchiede ^k   Serni, Sergio ^l   Siracusano, Salvatore ^m   Volpe, Alessandro ⁿ   Morgia, Giuseppe ^o   Bertini, Roberto ^p   Dalpiaz, Orietta ^d   Stief, Christian ^a   Ficarra, Vincenzo ^c,p,q  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e S Pio da Pietrelcina Hospital   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^j UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^k UNIVERSITY OF GENOA   (Italy)

^l UNIVERSITY OF FLORENCE   (Italy)

^m UNIVERSITY OF TRIESTE   (Italy)

ⁿ MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^o UNIVERSITY OF CATANIA   (Italy)

^p VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^q OLV HOSPITAL   (Belgium)

more..

Author keywords

cancer specific survival; early recurrence; late recurrence; nephrectomy; prognostic parameters; renal cell carcinoma (RCC); time to recurrence

Indexed keywords

ABDOMINAL METASTASIS; ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NEPHRECTOMY; NEPHRON SPARING SURGERY; PANCREAS METASTASIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE; SKIN METASTASIS; TIME TO RECURRENCE; TREATMENT DURATION; TUMOR INVASION; UNIVARIATE ANALYSIS;

CANCER-SPECIFIC SURVIVAL; EARLY RECURRENCE; LATE RECURRENCE; NEPHRECTOMY; PROGNOSTIC PARAMETERS; RENAL CELL CARCINOMA (RCC); TIME TO RECURRENCE;

AGED; CARCINOMA, RENAL CELL; DATABASES, FACTUAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84886090713     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12246     Document Type: Article

References (26)

1. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58: 398-406
2. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. Practice Guidelines Committee of the American Urological Association. J Urol 2009; 182: 1271-1279
3. Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009; 7: 618-630
4. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK,. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 2007; 109: 1763-1768
5. Nguyen MM, Gill IS, Ellison LM,. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J Urol 2006; 176: 2397-2400
6. Ljungberg B, Alamdari FI, Rasmuson T, Roos G,. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999; 84: 405-411
7. Breda A, Konijeti R, Lam JS,. Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. Expert Rev Anticancer Ther 2007; 7: 847-862
8. Nakano E, Fujioka H, Matsuda M, Osafune M, Takaha M, Sonoda T,. Late recurrence of renal cell carcinoma after nephrectomy. Eur Urol 1984; 10: 347-349
9. Brookman-May S, May M, Shariat SF, et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN project). Eur Urol 2012; doi: 10.1016/j.eururo.2012.06.030 [Epub ahead of print]
10. Rodriguez-Covarrubias F, Gomez-Alvarado MO, Sotomayor M, et al. Time to recurrence after nephrectomy as a predictor of cancer-specific survival in localized clear-cell renal cell carcinoma. Urol Int 2011; 86: 47-52
11. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P,. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006; 24: 3101-3106
12. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296
13. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-5799
14. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS,. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005; 174: 466-472
15. Frank I, Blute ML, Cheville JC, et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 2003; 170: 2225-2232
16. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20: 4559-4566
17. Adamy A, Chong KT, Chade D, et al. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 2011; 185: 433-438
18. Greene FL, Gospodarowicz M, Wittekend C, et al. American Joint Committee on Cancer (AJCC) Staging Manual, 7th edn. Philadalphia, PA: Springer, 2009
19. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumors. J Pathol 1997; 183: 131-133
20. Fuhrman S, Lasky LC, Limas L,. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663
21. Grambsch PM, Therneau TM, Fleming TR,. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 1995; 51: 1469-1482
22. Barlow WE, Prentice RL,. Residuals for relative risk regression. Biometrika 1988; 75: 65-74
23. Leõn LF, Tsai CL,. Functional form diagnostics for Cox's proportional hazards model. Biometrics 2004; 60: 75-84
24. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387
25. Lachin JM,. Power of the Mantel-Haenszel and other tests for discrete or grouped time-to-event data under a chained binomial model. Stat Med 2013; 32: 220-229
26. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005; 174: 1759-1763